Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Observational Study of TAS-102 (Suyuan) in Chinese Patients With Metastatic Colorectal Cancer
ChiCTR2400094728Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trifluridine + tipiracil in metastatic colorectal adenocarcinoma (mCRC), sponsored by Changhai Hospital. Primary endpoint: Safety Evaluation. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400094728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094728.